# Stryker Corporation (SYK) fundamentals

Data as of 2026-09-08. NYSE, United States. Sector: Healthcare / Health Care Technology. Price $303.13, market value $116.3 billion.

## Valuation
- **P/E (trailing): 31.4×** (5-yr avg 42.0×, 3-yr avg 40.9×). Stryker Corporation trades at 31.4× trailing earnings, well below its own five-year average of 42.0×: cheap by its own standards. The Healthcare median in the September 2026 study was 28.5×. Forward P/E is 18.1×, lower than trailing, so analysts expect earnings to grow.
- **PEG: 2.19**. A PEG of 2.19 means the P/E is high relative to expected earnings growth; the price already assumes a lot.
- **Price / sales: 4.5×**. Each dollar of revenue is priced at 4.5×.
- **Price / book: 4.8×**. The shares trade at 4.8× book value; book value is a meaningful part of the valuation.
- **EV / EBITDA: 17.9×**. Enterprise value is 17.9× operating earnings before depreciation, the multiple that ignores how the company is financed.
- **Free-cash-flow yield: 4.0%** (5-yr avg 2.7%). Free cash flow equals 4.0% of the market value, above its five-year average of 2.7%, so the shares are cheaper on cash than they have usually been.
- **Earnings yield: 3.2%**. The inverse of the P/E: 3.2% of the price is earned each year.

## Profitability
- **Gross margin: 65.0%**. Stryker Corporation keeps 65.0% of revenue after the direct cost of what it sells, the kind of margin that comes with software, brands or pricing power.
- **Operating margin: 21.4%**. 21.4% of revenue is left after running the business, a healthy level in most sectors.
- **Net margin: 12.9%**. 12.9% of each dollar of sales reaches the bottom line.
- **Return on equity: 14.5%**. 14.5% on shareholders' equity is solid.
- **Return on invested capital: 12.8%**. Return on all capital, debt included, is 12.8%.
- **Return on assets: 7.8%**. Each dollar of assets produces 7.8% of profit.

## Growth
- **Revenue growth (1 yr): 11.2%** (3-yr 10.8%/yr, 5-yr 11.8%/yr). Revenue grew 11.2% over the last year, against 11.8% a year compounded over five years.
- **EPS growth (1 yr): 8.2%** (3-yr 10.8%/yr, 5-yr 14.9%/yr). Earnings per share rose 8.2%, roughly in step with revenue.
- **Free-cash-flow growth (3 yr): 28.1%/yr**. Free cash flow has compounded at 28.1% a year over three years, keeping pace with earnings: the growth is real cash.

## Financial health
- **Debt to equity: 0.71**. Debt is 0.71 times equity, moderate leverage.
- **Net debt / EBITDA: 1.7×**. It would take 1.7 years of operating earnings to repay net borrowings, within the comfortable range.
- **Altman Z-score: 4.26**. A Z-score of 4.26 places the company in the safe zone for bankruptcy risk.
- **Piotroski F-score: 4/9**. 4 of 9 checks pass: mixed.

## Dividends
- **Dividend yield: 1.16%** ($3.48 per share, trailing). Stryker Corporation yields 1.16%, a modest yield more typical of a growth-oriented payer.
- **Payout ratio: 40%** (28% of free cash flow). 40% of earnings goes out as dividends, leaving room to keep raising it.
- **Consecutive years of increases: 16**. 16 straight years of increases, a record that survived at least one recession.
- **Dividend growth (5 yr): 7.6%/yr** (1-yr 4.9%). The dividend has grown 7.6% a year over five years.

## Price and momentum
- **Total return (1 yr): -22.3%** (YTD -13.3%, 3-mo -0.6%). The shares are down 22.3% over twelve months including dividends.
- **From 52-week high: -23.4%** (7.9% above the low). Trading 23% below its 52-week high.
- **200-day average: below**. The price sits below its 200-day moving average, the usual definition of a downtrend.
- **RSI (14-day): 34**. An RSI of 34 is neutral.
- **Beta (1 yr): 0.18** (volatility 28%). Beta of 0.18 against the S&P 500: the shares move much less than the market.

Live score and charts: https://foliofundamentals.com/analyzer?s=SYK · Page: https://foliofundamentals.com/stocks/syk

Not investment advice.